Safinamide mesylate
|
|
Safinamide mesylate 속성
- 녹는점
- 210° (dec)
- 알파
- D25 +12.9° (c = 1.1% in 98% acetic acid)
- 저장 조건
- 2-8°C
- 용해도
- H2O: ≥15mg/mL
- 물리적 상태
- 가루
- 색상
- 흰색에서 황갈색까지
- optical activity
- [α]/D +9.5 to +14°, c = 1 (95% acetic acid)
안전
- 위험 및 안전 성명
- 위험 및 사전주의 사항 (GHS)
유엔번호(UN No.) | UN 2811 6.1 / PGIII | ||
---|---|---|---|
WGK 독일 | 3 |
Safinamide mesylate C화학적 특성, 용도, 생산
개요
Safinamide methanesulfonate was approved in February 2015 by the EMA for the treatment of mid- to late-stage fluctuating Parkinson’s disease. This approval included use of the drug as an add-on therapy for use with levodopa, either alone or in combination with other existing therapies for Parkinson’s disease.51 Safinamide methanesulfonate, an oral α-aminoamide originally discovered by Farmitalia Carlo Erba and later developed by Newron/Zambon, functions as a highly selective and reversible inhibitor of MAO-B, leading to increased levels of dopamine and subsequent improvement in the motor symptoms of Parkinson’s disease, side effects that often result from use of other traditional treatments relying on dopamine replacement therapy.용도
Safinamide mesylate salt has been used as a reference drug to study its inhibitory effect on human monoamine oxidases (hMAO-A and hMAO-B).Mechanism of action
Safinamide employs several mechanisms of action, functioning as both a dopaminergic agent through inhibition of MAO-B as well as a nondopaminergic agent via selective calcium and sodium channel modulation, leading to inhibition of glutamate release. At least one of several clinical studies of patients with mid- to late-stage Parkinson’s disease showed increased daily ON time (periods of symptom control) without accompanying motor complications (dyskinesias) upon treatment with safinamide, while studies of early stage Parkinson’s disease patients treated with this drug showed significantly improved motor symptoms during the 18-month study. Additionally, safinamide is chemically and metabolically stable, is well tolerated in patients, and has not exhibited serious adverse effects even upon treatment at higher dosage ranges.부작용
Common adverse events in clinical trials (in more than 1% of people) included nausea, dizziness, tiredness, sleeplessness, or thostatic hypotension (low blood pressure) and headache. There was no significant difference in the occurrence of these effects between safinamide and placebo.Safinamide mesylate 준비 용품 및 원자재
원자재
준비 용품
Safinamide mesylate 공급 업체
글로벌( 238)공급 업체
공급자 | 전화 | 이메일 | 국가 | 제품 수 | 이점 |
---|---|---|---|---|---|
Hebei Yanxi Chemical Co., Ltd. | +8617531190177 |
peter@yan-xi.com | China | 5873 | 58 |
Hebei Chuanghai Biotechnology Co,.LTD | +86-13131129325 |
sales1@chuanghaibio.com | China | 5882 | 58 |
Capot Chemical Co.,Ltd. | 571-85586718 +8613336195806 |
sales@capotchem.com | China | 29798 | 60 |
Beijing Cooperate Pharmaceutical Co.,Ltd | 010-60279497 |
sales01@cooperate-pharm.com | CHINA | 1811 | 55 |
Hangzhou FandaChem Co.,Ltd. | 008657128800458; +8615858145714 |
fandachem@gmail.com | China | 9308 | 55 |
Nanjing ChemLin Chemical Industry Co., Ltd. | 025-83697070 |
product@chemlin.com.cn | CHINA | 3012 | 60 |
ATK CHEMICAL COMPANY LIMITED | +undefined-21-51877795 |
ivan@atkchemical.com | China | 32836 | 60 |
career henan chemical co | +86-0371-86658258 +8613203830695 |
sales@coreychem.com | China | 29888 | 58 |
Shaanxi Yikanglong Biotechnology Co., Ltd. | 17791478691 |
yklbiotech@163.com | CHINA | 296 | 58 |
Nanjing Dolon Biotechnology Co.,Ltd. | 18905173768 |
sales@dolonchem.com | CHINA | 2972 | 58 |
Safinamide mesylate 관련 검색:
Safinamide Impurity 3
Safinamide Impurity 6
Safinamide-d4
FCE 28073
Safinamide Impurity 9
(S)-2-((2-((3-fluorobenzyl)oxy)benzyl)amino)propanamide
(S)-2-((4-(benzyloxy)benzyl)amino)propanamide
Safinamide Impurity 11
Safinamide Impurity 5
Tenofovir
Obeticholic Acid
Safinamide
Dizocilpine
Gemcitabine hydrochloride
7-Ethyl-10-hydroxycamptothecin
Tideglusib
Lenvatinib
LY 294002 HYDROCHLORIDE